Health
Anti-SARS-CoV-2 drug candidate enters phase I clinical trial – News-Medical.Net
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of…
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.
Researchers found that DC402234 exhibits effective inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 0.053 ± 0.005 μM,…
-
Noosa News23 hours agoRoom-naming honour for rights champion – Proctor
-
General18 hours agoEmbrace AI or risk future ruin, tech billionaire warns
-
Noosa News23 hours agoMystery surrounding identity of young man found dead in Toohey Forest sparks public appeal
-
Business19 hours ago3 perfect ASX ETFs for beginners